Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06777433 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
A Phase 2 study of Brain Metastases From Solid Tumors, sponsored by Radiopharm Theranostics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT06777433: Recruiting Phase 2 study of Brain Metastases From Solid Tumors, sponsored by Radiopharm Theranostics.
NCT06777433 is a Phase 2 study of Brain Metastases From Solid Tumors that is actively recruiting participants, run by Radiopharm Theranostics. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06777433, a Phase 2 study of Brain Metastases From Solid Tumors, is actively recruiting participants, sponsored by Radiopharm Theranostics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is an open-label, single dose, single arm, multicenter Phase 2b study to establish the imaging performance of RAD101 PET in participants who are ≥ 18 years of age and with suspected recurrent brain metastases from solid tumors. The study consists of a 4-week Screening Period, a 3-day Imaging and Safety Follow-Up Period, and a Data Collection Period of up to 6 months. Participant eligibility will be determined during the Screening Period and eligible participants will be enrolled in the study. On Day 1, the enrolled participants will receive a single dose of the investigational medicinal product (IMP), RAD101. Participants will then proceed with a whole brain PET scan. A high-resolution Magnetic Resonance Imaging (MRI) will be performed in joint acquisition with PET or separately on the same day, or on the day prior to or the day following RAD101 administration. For applicable study sites where PK samples will be collected, whole body PET scans will be performed, blood samples will be drawn, and urine will be collected throughout the scanning period. A phone follow-up will be performed on Day 3 (+ 1 day). Participants will have follow-up (longitudinal) MRI (otherwise CT) scans (longitudinal imaging) and/ or a biopsy according to their Standard of Care (SoC). The longitudinal image results, and details of the biopsy if performed as part of SoC (i.e., location and histopathology results), will be collected during the 6- month Data Collection Period.
Primary Outcome
Number, size, and proportion of SRS/SRT-treated lesions identified by both RAD101 PET/MRI and MRI (with macrocyclic gadolinium)
Conditions Studied
Interventions
- DRUG RAD101 (18F-FPIA)
Study Locations (5)
Michigan
- University of Michigan - Ann Arbor
- Karmanos Cancer Institute - Detroit
- BAMF Health - Grand Rapids
Illinois
- Ascension Illinois Oncology Research - Hoffman Estates
Indiana
- Goshen Center for Cancer Care - Goshen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-12-13 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What NCT06777433 shows while recruiting
NCT06777433 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Brain Metastases From Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which RAD101 (18F-FPIA) is the first listed.
NCT06777433 lists 5 locations in 3 states (Michigan, Illinois, Indiana).
Frequently Asked Questions
What is clinical trial NCT06777433 about?
NCT06777433 is a clinical study titled "Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases". This is an open-label, single dose, single arm, multicenter Phase 2b study to establish the imaging performance of RAD101 PET in participants who are ≥ 18 years of age and with suspected recurrent brain metastases from solid tumors. The study consists of a 4-week Screening Period, a 3-day Imaging a...
What is the current status of trial NCT06777433?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2024-12-13. Estimated completion is 2026-06.
What conditions does trial NCT06777433 study?
This clinical trial studies the following conditions: Brain Metastases From Solid Tumors.
What interventions are being tested in trial NCT06777433?
The interventions under investigation include: RAD101 (18F-FPIA) (DRUG).
Who is sponsoring clinical trial NCT06777433?
This trial is sponsored by Radiopharm Theranostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06777433 being conducted?
This trial has 5 study locations across Illinois, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases From Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06777433's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI